Hub : Traits :

Angina

49 significantly associated models · 16 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	109098737	110517617	3	1	3.3e-12	3.3e-12	2.2e-01	97	SORT1
2	1	222133118	223529093	1	1	7.2e-08	7.8e-07	5.9e-01	99	RP11-378J18.8
3	6	12020241	13990267	2	1	2.3e-08	2.5e-08	1.0e+00	100	RP1-257A7.5
4	6	133961374	134468561	1	1	1.6e-09	9.0e-08	7.3e-01	100	TCF21
5	6	160071844	161571560	2	2	9.0e-08	5.2e-16	1.7e-08	52	SLC22A1 SLC22A3
6	9	21303958	22819407	2	2	2.2e-22	1.2e-34	1.6e-14	61	CDKN2B CDKN2B-AS1
7	15	78360691	79802863	2	2	9.8e-11	5.7e-10	2.7e-01	97	ADAMTS7
8	15	90718541	92135418	2	1	1.3e-11	1.4e-08	4.3e-01	98	FES
9	17	47119135	47685050	1	1	8.0e-08	2.3e-09	8.5e-03	81	ZNF652

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.73	1	0	0.0	0.00	1.0e+00	FES
Bipolar Disorder or Schizophrenia	3.18	1	1	2.2	0.00	1.0e+00	FES
Neuroticism (Nagel 2018)	1.33	2	0	0.0	0.00	1.0e+00	FES SLC22A1
Schizophrenia (2018)	2.96	1	1	2.2	0.00	1.0e+00	FES
Worry (Nagel 2018)	0.95	1	0	0.0	0.00	1.0e+00	SLC22A1
Reaction Time	1.31	1	0	0.0	0.00	1.0e+00	ZNF652
Breast Cancer	2.52	3	0	0.0	0.00	1.0e+00	CDKN2B CDKN2B-AS1 FES
Age at First Birth	1.68	1	0	0.0	0.00	1.0e+00	ZNF652
Coronary Artery Disease (CAD)	28.57	6	4	8.9	0.99	1.4e-05	ADAMTS7 CDKN2B CDKN2B-AS1 RP1-257A7.5 SLC22A3 TCF21
HDL Cholesterol	2.13	1	1	2.2	0.00	1.0e+00	SORT1
LDL Cholesterol	43.35	1	1	2.2	0.00	1.0e+00	SORT1
Schizophrenia (2014)	3.01	1	1	2.2	0.00	1.0e+00	FES
Triglycerides	1.61	1	0	0.0	0.00	1.0e+00	ZNF652
Type 2 Diabetes (T2D) (2012)	3.21	1	0	0.0	0.00	1.0e+00	CDKN2B
Blood Eosinophil Count	2.19	1	1	2.2	0.00	1.0e+00	ZNF652
Blood Platelet Count	0.80	3	1	2.2	0.97	3.2e-02	ADAMTS7 CDKN2B SLC22A3
Blood Red Count	0.63	4	0	0.0	0.27	7.3e-01	FES RP1-257A7.5 TCF21 ZNF652
Blood White Count	1.20	3	1	2.2	0.00	1.0e+00	CDKN2B FES ZNF652
Heel T-Score	0.33	1	0	0.0	0.00	1.0e+00	SORT1
BMI	0.94	2	0	0.0	0.00	1.0e+00	SLC22A3 ZNF652
Height	1.26	4	4	8.9	-0.91	9.0e-02	FES SLC22A3 SORT1 ZNF652
Waist Hip Ratio (WHR)	2.13	2	1	2.2	0.00	1.0e+00	ADAMTS7 SLC22A3
Systolic Blood Pressure	7.01	7	4	8.9	0.53	2.2e-01	ADAMTS7 FES RP1-257A7.5 SLC22A1 SLC22A3 TCF21 ZNF652
Smoking Status	3.01	3	0	0.0	0.00	1.0e+00	FES SORT1 ZNF652
Allergy or Eczema	2.47	2	1	2.2	0.00	1.0e+00	FES ZNF652
Cardiovascular Disease	10.99	6	5	11.1	0.95	3.8e-03	FES SLC22A1 SLC22A3 SORT1 TCF21 ZNF652
Respiratory disease	3.20	2	1	2.2	0.00	1.0e+00	FES ZNF652
Type 2 Diabetes (T2D) (2018)	1.38	1	0	0.0	0.00	1.0e+00	SLC22A3
Lung FEV1/FVC ratio	2.05	4	1	2.2	0.58	4.2e-01	RP11-378J18.8 SORT1 TCF21 ZNF652
Lung FVC	1.02	1	1	2.2	0.00	1.0e+00	TCF21
Neuroticism	1.28	1	0	0.0	0.00	1.0e+00	SLC22A1
Hair Pigment	0.49	4	3	6.7	-0.80	2.0e-01	ADAMTS7 CDKN2B CDKN2B-AS1 FES
Hand grip strength (left)	1.73	2	1	2.2	0.00	1.0e+00	FES RP1-257A7.5
Number of treatments/medications taken	5.24	3	2	4.4	0.00	1.0e+00	FES SORT1 ZNF652
Sensitivity / hurt feelings	1.85	1	1	2.2	0.00	1.0e+00	FES
Systolic blood pressure, automated reading	5.50	2	1	2.2	0.00	1.0e+00	FES RP1-257A7.5
Medication: Metformin	1.63	1	0	0.0	0.00	1.0e+00	CDKN2B
Pack years adult smoking proportion	7.44	1	1	2.2	0.00	1.0e+00	ADAMTS7
Impedance of leg (right)	2.60	2	2	4.4	0.00	1.0e+00	FES ZNF652
Leg fat-free mass (left)	1.05	2	0	0.0	0.00	1.0e+00	FES SLC22A3
Trunk fat percentage	1.19	1	0	0.0	0.00	1.0e+00	SLC22A3
Hand grip strength (right)	1.20	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Taking other prescription medications	2.44	1	1	2.2	0.00	1.0e+00	ZNF652
Age when periods started (menarche)	1.16	1	0	0.0	0.00	1.0e+00	ZNF652
High blood pressure	7.89	3	2	4.4	0.00	1.0e+00	FES TCF21 ZNF652
Hayfever, allergic rhinitis or eczema	2.54	2	1	2.2	0.00	1.0e+00	FES ZNF652
Multivitamins +/- minerals	1.99	1	0	0.0	0.00	1.0e+00	ADAMTS7
Medication: Atenolol	7.76	2	1	2.2	0.00	1.0e+00	CDKN2B FES
Sitting height	1.17	4	1	2.2	-0.32	6.8e-01	ADAMTS7 FES SLC22A3 ZNF652
Chronic bronchitis/emphysema (father)	4.39	1	0	0.0	0.00	1.0e+00	ADAMTS7
High blood pressure (mother)	8.02	2	1	2.2	0.00	1.0e+00	FES RP1-257A7.5
Impedance of leg (left)	2.49	2	2	4.4	0.00	1.0e+00	FES ZNF652
Leg predicted mass (left)	1.05	2	0	0.0	0.00	1.0e+00	FES SLC22A3
Trunk fat mass	1.14	1	0	0.0	0.00	1.0e+00	SLC22A3
Number of incorrect matches in round	1.40	1	0	0.0	0.00	1.0e+00	FES
Past tobacco smoking	2.76	2	0	0.0	0.00	1.0e+00	CDKN2B-AS1 ZNF652
Alcohol usually taken with meals	2.51	2	0	0.0	0.00	1.0e+00	FES ZNF652
Heart attack	25.95	11	8	17.8	0.98	2.8e-07	ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3 SORT1 TCF21 ZNF652
Allergy	3.43	2	1	2.2	0.00	1.0e+00	FES ZNF652
Medication: Ramipril	5.17	2	0	0.0	0.00	1.0e+00	FES ZNF652
Medication: Simvastatin	14.50	7	2	4.4	0.90	5.7e-03	CDKN2B CDKN2B-AS1 FES RP11-378J18.8 SLC22A1 SLC22A3 SORT1
Illnesses of siblings	3.78	2	1	2.2	0.00	1.0e+00	FES ZNF652
Weight	0.87	1	0	0.0	0.00	1.0e+00	SLC22A3
Impedance of arm (right)	1.64	2	1	2.2	0.00	1.0e+00	CDKN2B ZNF652
Arm fat percentage (right)	1.05	1	0	0.0	0.00	1.0e+00	SLC22A3
Trunk fat-free mass	0.91	2	0	0.0	0.00	1.0e+00	SLC22A3 SORT1
Hip circumference	1.22	2	1	2.2	0.00	1.0e+00	ADAMTS7 SLC22A3
Father's age at death	7.34	4	1	2.2	-1.00	2.3e-03	CDKN2B CDKN2B-AS1 FES SORT1
Number of live births	1.38	1	0	0.0	0.00	1.0e+00	FES
Pulse rate	2.92	2	1	2.2	0.00	1.0e+00	SLC22A1 TCF21
Asthma	3.44	2	1	2.2	0.00	1.0e+00	FES ZNF652
Medication: Ibuprofen (e.g. Nurofen)	3.82	2	1	2.2	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Medication: Cholesterol lowering	21.78	8	3	6.7	0.89	3.1e-03	CDKN2B CDKN2B-AS1 FES RP11-378J18.8 SLC22A1 SLC22A3 SORT1 TCF21
Lung cancer (father)	4.71	1	0	0.0	0.00	1.0e+00	ADAMTS7
Illnesses of mother	6.30	3	1	2.2	0.00	1.0e+00	CDKN2B FES ZNF652
Pulse wave Arterial Stiffness index	3.87	2	0	0.0	0.00	1.0e+00	FES RP1-257A7.5
Impedance of arm (left)	1.56	1	1	2.2	0.00	1.0e+00	ZNF652
Arm fat mass (right)	0.95	1	0	0.0	0.00	1.0e+00	SLC22A3
Trunk predicted mass	0.89	2	0	0.0	0.00	1.0e+00	SLC22A3 SORT1
Standing height	1.14	3	3	6.7	0.00	1.0e+00	SLC22A3 SORT1 ZNF652
Breastfed as a baby	1.53	1	0	0.0	0.00	1.0e+00	FES
Hair/balding pattern: Pattern 4	1.12	1	0	0.0	0.00	1.0e+00	FES
Birth weight of first child	4.04	2	1	2.2	0.00	1.0e+00	FES TCF21
Peak expiratory flow (PEF)	1.59	1	1	2.2	0.00	1.0e+00	TCF21
Medication: Paracetamol	2.06	1	1	2.2	0.00	1.0e+00	RP1-257A7.5
Headache pain in last month	4.89	3	1	2.2	0.00	1.0e+00	FES RP1-257A7.5 ZNF652
Medication for cholesterol, blood pressure or diabetes	12.27	5	2	4.4	-0.91	3.3e-02	FES SLC22A1 SORT1 TCF21 ZNF652
Glaucoma (self-reported)	6.10	2	1	2.2	0.00	1.0e+00	CDKN2B CDKN2B-AS1
Medication: Amlodipine	4.29	2	1	2.2	0.00	1.0e+00	FES TCF21
Medication: Ventolin 100micrograms inhaler	2.11	1	0	0.0	0.00	1.0e+00	ZNF652
Birth weight	2.04	1	1	2.2	0.00	1.0e+00	FES
Chronic bronchitis/emphysema (mother)	2.76	1	0	0.0	0.00	1.0e+00	ADAMTS7
High blood pressure (siblings)	3.50	1	1	2.2	0.00	1.0e+00	FES
Forced vital capacity (FVC), Best measure	0.74	1	0	0.0	0.00	1.0e+00	TCF21
Body fat percentage	1.07	1	0	0.0	0.00	1.0e+00	SLC22A3
Leg fat percentage (right)	0.98	1	0	0.0	0.00	1.0e+00	RP11-378J18.8
Arm fat-free mass (right)	0.74	2	0	0.0	0.00	1.0e+00	SLC22A3 SORT1
Comparative body size at age 10	1.87	1	1	2.2	0.00	1.0e+00	ZNF652
Wheeze or whistling in the chest in last year	1.55	1	0	0.0	0.00	1.0e+00	ZNF652
Pulse wave peak to peak time	3.74	2	0	0.0	0.00	1.0e+00	FES RP1-257A7.5
Medication for pain relief, constipation, heartburn	3.27	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SORT1
Medication: Blood pressure	8.40	4	2	4.4	0.84	1.6e-01	FES SLC22A1 TCF21 ZNF652
Angina (self-reported)	33.85	11	10	22.2	1.00	2.9e-16	ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3 SORT1 TCF21 ZNF652
Migraine (self-reported)	5.16	1	1	2.2	0.00	1.0e+00	RP1-257A7.5
Medication: Ibuprofen	4.06	2	1	2.2	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Medication: Seretide 50 evohaler	2.58	1	0	0.0	0.00	1.0e+00	ZNF652
Mean time to correctly identify matches	1.66	1	0	0.0	0.00	1.0e+00	FES
Heart disease (mother)	16.40	8	3	6.7	0.96	3.7e-05	ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3
Whole body fat mass	1.03	1	0	0.0	0.00	1.0e+00	SLC22A3
Leg fat mass (right)	0.80	1	0	0.0	0.00	1.0e+00	SLC22A3
Arm predicted mass (right)	0.77	2	0	0.0	0.00	1.0e+00	SLC22A3 SORT1
Pulse rate, automated reading	3.72	4	1	2.2	0.70	3.0e-01	RP11-378J18.8 RP1-257A7.5 SORT1 TCF21
Alcohol intake frequency.	1.87	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Comparative height size at age 10	1.07	3	0	0.0	0.00	1.0e+00	FES SLC22A3 SORT1
Overall health rating	2.27	1	1	2.2	0.00	1.0e+00	ZNF652
Chest pain or discomfort	3.88	1	0	0.0	0.00	1.0e+00	CDKN2B
Had major operations	3.22	1	0	0.0	0.00	1.0e+00	ZNF652
Medication: Aspirin	15.09	7	5	11.1	0.99	4.2e-05	CDKN2B CDKN2B-AS1 FES SLC22A1 SLC22A3 SORT1 TCF21
Hypertension (Self-reported)	8.11	4	2	4.4	0.87	1.3e-01	FES SLC22A3 TCF21 ZNF652
Illnesses of father: Heart disease	28.53	10	8	17.8	0.99	1.3e-08	ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3 SORT1 TCF21
Smoking status: Previous	2.06	1	0	0.0	0.00	1.0e+00	CDKN2B-AS1
Whole body fat-free mass	0.94	3	0	0.0	0.00	1.0e+00	FES SLC22A3 SORT1
Leg fat-free mass (right)	1.11	3	0	0.0	0.00	1.0e+00	FES SLC22A3 SORT1
Handedness (chirality/laterality): Left-handed	1.93	1	0	0.0	0.00	1.0e+00	FES
Long-standing illness, disability or infirmity	2.55	2	0	0.0	0.00	1.0e+00	CDKN2B ZNF652
Diabetes diagnosed by doctor	1.33	1	0	0.0	0.00	1.0e+00	SLC22A3
Medication for cholesterol	6.70	4	2	4.4	-1.00	8.8e-04	FES SLC22A3 SORT1 ZNF652
Mineral and other dietary supplements	3.10	1	0	0.0	0.00	1.0e+00	FES
Breast cancer (self-reported)	2.67	1	0	0.0	0.00	1.0e+00	CDKN2B
Asthma (self-reported)	3.41	2	1	2.2	0.00	1.0e+00	FES ZNF652
Medication: Aspirin	15.56	7	5	11.1	0.99	4.5e-05	CDKN2B CDKN2B-AS1 FES SLC22A1 SLC22A3 SORT1 TCF21
Illnesses of father: None of the above (group 1)	10.34	4	2	4.4	-0.98	1.8e-02	CDKN2B CDKN2B-AS1 FES SLC22A3
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.86	1	0	0.0	0.00	1.0e+00	ADAMTS7
Whole body water mass	0.91	3	0	0.0	0.00	1.0e+00	FES SLC22A3 SORT1
Leg predicted mass (right)	1.13	3	0	0.0	0.00	1.0e+00	FES SLC22A3 SORT1
Arm fat mass (left)	0.92	1	0	0.0	0.00	1.0e+00	SLC22A3
Number of self-reported non-cancer illnesses	3.96	1	1	2.2	0.00	1.0e+00	ZNF652
Mother's age at death	2.08	1	0	0.0	0.00	1.0e+00	SLC22A1
Eye problems/disorders: Glaucoma	7.27	2	2	4.4	0.00	1.0e+00	CDKN2B CDKN2B-AS1
Medication: Blood pressure	6.71	4	1	2.2	0.70	3.0e-01	ADAMTS7 FES SLC22A3 ZNF652
Supplements: Fish oil (including cod liver oil)	2.66	1	0	0.0	0.00	1.0e+00	SLC22A3
High cholesterol (Self-reported)	22.24	5	3	6.7	0.79	1.1e-01	FES RP11-378J18.8 SLC22A1 SLC22A3 SORT1
Medication: Bendroflumethiazide	5.52	3	1	2.2	0.00	1.0e+00	ADAMTS7 FES TCF21
Medication: Paracetamol	1.77	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Medication: Lisinopril	2.26	1	0	0.0	0.00	1.0e+00	FES
Medication: Atorvastatin	17.30	5	3	6.7	0.96	1.0e-02	CDKN2B CDKN2B-AS1 SLC22A1 SLC22A3 SORT1
Illnesses of father: High blood pressure	5.02	1	1	2.2	0.00	1.0e+00	FES
Ever smoked	2.40	2	0	0.0	0.00	1.0e+00	FES ZNF652
Basal metabolic rate	0.91	3	0	0.0	0.00	1.0e+00	FES SLC22A3 SORT1
Arm fat-free mass (left)	0.72	2	0	0.0	0.00	1.0e+00	SLC22A3 SORT1
Number of operations (self-reported)	1.79	1	0	0.0	0.00	1.0e+00	ZNF652
Risk taking	2.14	1	0	0.0	0.00	1.0e+00	FES
Age started oral contraceptive pill	2.31	2	0	0.0	0.00	1.0e+00	FES ZNF652
Diastolic blood pressure, automated reading	7.25	5	3	6.7	0.70	1.9e-01	ADAMTS7 CDKN2B CDKN2B-AS1 FES ZNF652
Vascular/heart problems diagnosed by doctor	10.24	5	3	6.7	-0.91	3.0e-02	CDKN2B FES SLC22A3 TCF21 ZNF652
Cholesterol lowering medication	12.58	4	2	4.4	0.88	1.2e-01	CDKN2B SLC22A1 SLC22A3 SORT1
Medication: Omeprazole (e.g. Zanprol)	1.52	1	0	0.0	0.00	1.0e+00	TCF21
Pain experienced in last month	1.59	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Basal cell carcinoma (self-reported)	3.09	1	0	0.0	0.00	1.0e+00	CDKN2B
Heart attack/myocardial infarction (self-reported)	26.15	11	8	17.8	0.98	3.4e-07	ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3 SORT1 TCF21 ZNF652
Heart disease (siblings)	12.22	7	1	2.2	0.97	3.9e-04	ADAMTS7 CDKN2B-AS1 FES RP1-257A7.5 SLC22A1 SLC22A3 SORT1
Pack years of smoking	6.67	1	1	2.2	0.00	1.0e+00	ADAMTS7
Impedance of whole body	2.05	1	1	2.2	0.00	1.0e+00	ZNF652
Leg fat mass (left)	0.71	1	0	0.0	0.00	1.0e+00	SLC22A3
Arm predicted mass (left)	0.77	2	0	0.0	0.00	1.0e+00	SLC22A3 SORT1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	0	0.000	1.3
GTEx	Adipose Visceral Omentum	1	0.049	1.3
GTEx	Adrenal Gland	0	0.000	1.3
GTEx	Artery Aorta	2	0.067	1.4
GTEx	Artery Coronary	0	0.000	1.3
GTEx	Artery Tibial	3	0.080	1.4
GTEx	Brain Caudate basal ganglia	0	0.000	1.3
GTEx	Brain Cerebellar Hemisphere	1	0.067	1.3
GTEx	Brain Cerebellum	0	0.000	1.3
GTEx	Brain Cortex	0	0.000	1.4
GTEx	Brain Frontal Cortex BA9	0	0.000	1.4
GTEx	Brain Hippocampus	0	0.000	1.3
GTEx	Brain Hypothalamus	0	0.000	1.2
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.3
GTEx	Brain Putamen basal ganglia	0	0.000	1.2
GTEx	Breast Mammary Tissue	0	0.000	1.3
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.2
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.2
GTEx	Cells EBV-transformed lymphocytes	1	0.070	1.4
GTEx	Cells Transformed fibroblasts	1	0.024	1.3
GTEx	Colon Sigmoid	0	0.000	1.2
GTEx	Colon Transverse	0	0.000	1.3
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.3
GTEx	Esophagus Mucosa	1	0.030	1.3
GTEx	Esophagus Muscularis	0	0.000	1.3
GTEx	Heart Atrial Appendage	0	0.000	1.3
GTEx	Heart Left Ventricle	0	0.000	1.3
GTEx	Liver	1	0.139	1.4
GTEx	Lung	1	0.035	1.3
GTEx	Muscle Skeletal	1	0.035	1.3
GTEx	Nerve Tibial	0	0.000	1.3
GTEx	Ovary	0	0.000	1.3
GTEx	Pancreas	0	0.000	1.3
GTEx	Pituitary	0	0.000	1.3
GTEx	Prostate	0	0.000	1.3
GTEx	Skin Not Sun Exposed Suprapubic	0	0.000	1.3
GTEx	Skin Sun Exposed Lower leg	1	0.027	1.4
GTEx	Small Intestine Terminal Ileum	0	0.000	1.4
GTEx	Spleen	0	0.000	1.3
GTEx	Stomach	0	0.000	1.3
GTEx	Testis	0	0.000	1.3
GTEx	Thyroid	1	0.025	1.3
GTEx	Uterus	0	0.000	1.3
GTEx	Vagina	0	0.000	1.4
GTEx	Whole Blood	1	0.050	1.3
METSIM	Adipose	1	0.022	1.3
NTR	Blood	0	0.000	1.3
ROSMAP	Brain Pre-frontal Cortex	2	0.046	1.3
YFS	Blood	1	0.022	1.3
CommonMind	Brain Pre-frontal Cortex	5	0.093	1.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.4
The Cancer Genome Atlas	Breast Invasive Carcinoma	3	0.068	1.3
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	1	0.091	1.4
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	1.4
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.4
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.3
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	1	0.037	1.4
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	1	0.024	1.3
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	1	0.023	1.3
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.4
The Cancer Genome Atlas	Lung Adenocarcinoma	2	0.068	1.4
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	1	0.040	1.4
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	1	0.063	1.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.3
The Cancer Genome Atlas	Prostate Adenocarcinoma	1	0.022	1.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.3
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.4
The Cancer Genome Atlas	Stomach Adenocarcinoma	1	0.059	1.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.4
The Cancer Genome Atlas	Thyroid Carcinoma	1	0.019	1.3
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.4